Search Results - "Rudin, Dan"

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A by Konkle, Barbara A, Shapiro, Amy D, Quon, Doris V, Staber, Janice M, Kulkarni, Roshni, Ragni, Margaret V, Chhabra, Ekta S, Poloskey, Stacey, Rice, Kara, Katragadda, Suresh, Fruebis, Joachim, Benson, Craig C

“…In a study involving patients with severe hemophilia A, an injection of the novel fusion protein BIVV001 resulted in a duration of factor VIII activity that…”
Get full text

A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa by Tang, Jean Yuh, Marinkovich, M Peter, Lucas, Eleanor, Gorell, Emily, Chiou, Albert, Lu, Ying, Gillon, Jodie, Patel, Dipen, Rudin, Dan

“…Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic collagen disorder characterized by skin fragility leading to blistering, wounds, and scarring…”
Get full text

Inadequacy of current pediatric epinephrine autoinjector needle length for use in infants and toddlers by Kim, Harold, MD, Dinakar, Chitra, MD, McInnis, Paul, Bsc, Rudin, Dan, MD, Benain, Xavier, MD, Daley, William, MD, MPH, Platz, Elke, MD, MS

“…Abstract Background Epinephrine injection represents the standard of care for anaphylaxis treatment. It is most effective if delivered intramuscularly, whereas…”
Get full text

A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa by Paller, Amy S, Pope, Elena, Rudin, Dan, Malyala, Anna, Ramsdell, Deborah, Johnson, Ramsey, Landy, Hal, Murrell, Dedee F

“…Abstract Background Standardized assessments for dystrophic epidermolysis bullosa (DEB) are needed. This prospective, multicenter, 4-week, observational study…”
Get full text

Dentistry for the Ages Series--A Gross Omission by Rudin, Dan E

Get full text

Frequently overlooked and rarely listened to: music therapy in gastrointestinal endoscopic procedures by Rudin, Dan

“…To elucidate the role of music therapy in gastrointestinal endoscopic procedures following the conflicting outcomes reported in two recent studies. The…”
Get full text

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers by Shaik, M. Naveed, LaBadie, Robert R., Rudin, Dan, Levin, Wendy J.

“…Purpose To evaluate the effect of a potent cytochrome P450 3A4 (CYP3A4) inhibitor, ketoconazole, and separately the effect of food on PF-04449913…”
Get full text

Sonographic Assessment of Optimal Needle Length for Epinephrine Autoinjectors in Infants and Toddlers by Kim, Harold L., MD, Dinakar, Chitra, MD, FAAAAI, McInnis, Paul, BEng, Rudin, Dan, MD, Daley, William, MD, MPH, Platz, Elke, MD, MS

“…Methods Infants and toddlers weighing 7.5-15 kg, recruited from two North American ambulatory allergy clinics underwent baseline and compression (10 pounds…”
Get full text

Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study by Rudin, Dan, MD

Get full text

Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: Meta-analysis of randomized placebo-controlled trials by Rudin, Dan, Kiss, Alexander, Wetz, Robert V, Sottile, Vincent M

“…Background and Aim:  Prior studies have suggested the efficacy of somatostatin and gabexate in post‐endoscopic retrograde cholangiopancreatography (ERCP)…”
Get full text

Good physicians from the perspective of their patients by Schattner, Ami, Rudin, Dan, Jellin, Navah

“…It is not currently known what is the patient's viewpoint of a "good" physician. We set out to define patient's priorities regarding different physician's…”
Get full text

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study by Nolan, Beatrice, Mahlangu, Johnny, Pabinger, Ingrid, Young, Guy, Konkle, Barbara A., Barnes, Chris, Nogami, Keiji, Santagostino, Elena, Pasi, K. John, Khoo, Liane, Winding, Bent, Yuan, Huixing, Fruebis, Joachim, Rudin, Dan, Oldenburg, Johannes

“…Introduction The efficacy and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc) as an extended half‐life treatment for severe haemophilia A were…”
Get full text

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects by Banfield, Christopher, Rudin, Dan, Bhattacharya, Indranil, Goteti, Kosalaram, Li, Gang, Hassan‐Zahraee, Mina, Brown, Lisa S., Hung, Kenneth E., Pawlak, Sylvester, Lepsy, Christopher

“…Aims Human genetic, tissue expression, proteomics, transcriptomics and nonclinical studies implicate tumour necrosis factor α‐like ligand 1A (TL1A) as a novel…”
Get full text

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study by Pasi, K. John, Fischer, Kathelijn, Ragni, Margaret, Kulkarni, Roshni, Ozelo, Margareth C., Mahlangu, Johnny, Shapiro, Amy, P’Ng, Stephanie, Chambost, Hervé, Nolan, Beatrice, Bennett, Carolyn, Matsushita, Tadashi, Winding, Bent, Fruebis, Joachim, Yuan, Huixing, Rudin, Dan, Oldenburg, Johannes

“…Introduction Recombinant factor IX Fc fusion protein (rFIXFc) has demonstrated efficacy for treatment of haemophilia B in the Phase 3 B‐LONG and Kids B‐LONG…”
Get full text

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01) by Yin, Donghua, Barker, Kerry B., Li, Ruifeng, Meng, Xu, Reich, Steven D., Ricart, Alejandro D., Rudin, Dan, Taylor, Carrie T., Zacharchuk, Charles M., Hansson, Arne G.

“…Aims The pharmacokinetic (PK) similarity between PF‐05280014, a proposed trastuzumab biosimilar, trastuzumab sourced from European Union (trastuzumab‐EU) or…”
Get full text

Evaluation of Glucosylceramide Synthase (GCS) Inhibition for GBA-Associated Parkinson’s Disease (P3.051) by Fischer, Tanya, Sardi, S. Pablo, Shihabuddin, Lamya, Rudin, Dan, Sharma, Jyoti, Araujo, Roberto, Li, Jian, Peterschmitt, M. Judith

“…Abstract only…”
Get full text

Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1 by Li, Jing, Chen, Jun, Kanamaluru, Vanaja, Gaemers, Sebastiaan J.M., Peterschmitt, M. Judith, Hou, Audrey W., Xue, Yong, Turpault, Sandrine, Rudin, Dan

“…Eliglustat is a first-line oral therapy for adults with Gaucher disease type 1 (GD1) who have extensive (EM), intermediate (IM), or poor (PM) CYP2D6…”
Get full text

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B by Ragni, Margaret, Kulkarni, Roshni, Pasi, K. John, Fischer, Kathelijn, Mahlangu, Johnny, Shapiro, Amy, Nolan, Beatrice, Oldenburg, Johannes, Matsushita, Tadashi, Willemze, Annemieke, Yuan, Huixing, Rudin, Dan

“…▪ Introduction: Recombinant factor IX Fc fusion protein (rFIXFc) is an extended half-life therapy for severe hemophilia B. The safety, efficacy, and prolonged…”
Get full text

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer by Konkle, Barbara A, Shapiro, Amy, Quon, Doris, Staber, Janice, Suzuki, Takashi, Poloskey, Stacey, Rice, Kara, Katragadda, Suresh, Rudin, Dan, Fruebis, Joachim

“…Introduction: The standard of care for patients with severe hemophilia A is prophylactic factor VIII (FVIII) replacement. Conventional recombinant FVIII…”
Get full text

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A by Nolan, Beatrice, Mahlangu, Johnny, Young, Guy, Konkle, Barbara A, Pasi, K. John, Oldenburg, Johannes, Nogami, Keiji, Tripkovic, Nikola, Yuan, Huixing, Rudin, Dan

“…Introduction: Prophylactic replacement of coagulation factor VIII (FVIII) is the standard of care in hemophilia A, given its natural mechanism of action,…”
Get full text